Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A report from the INVEST-STEMI group

The use of intravenous antiplatelet therapy during primary percutaneous coronary intervention (PPCI) is not fully standardized. The aim is to evaluate the effectiveness and safety of periprocedural intravenous administration of cangrelor or tirofiban in a contemporary ST-segment elevation myocardial...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2024-06, Vol.57 (5), p.757-766
Main Authors: Silverio, Angelo, Bellino, Michele, Scudiero, Fernando, Attisano, Tiziana, Baldi, Cesare, Catalano, Angelo, Centore, Mario, Cesaro, Arturo, Di Maio, Marco, Esposito, Luca, Granata, Giovanni, Maiellaro, Francesco, Muraca, Iacopo, Musumeci, Giuseppe, Parodi, Guido, Personeni, Davide, Valenti, Renato, Vecchione, Carmine, Calabrò, Paolo, Galasso, Gennaro
Format: Article
Language:English
Subjects:
Cardiology
Hematology
Medicine
Medicine & Public Health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of intravenous antiplatelet therapy during primary percutaneous coronary intervention (PPCI) is not fully standardized. The aim is to evaluate the effectiveness and safety of periprocedural intravenous administration of cangrelor or tirofiban in a contemporary ST-segment elevation myocardial infarction (STEMI) population undergoing PPCI. This was a multicenter prospective cohort study including consecutive STEMI patients who received cangrelor or tirofiban during PPCI at seven Italian centers. The primary effectiveness measure was the angiographic evidence of thrombolysis in myocardial infarction (TIMI) flow 
ISSN:1573-742X
1573-742X
DOI:10.1007/s11239-024-02970-7